Literature DB >> 31466581

Update on Current Treatment Recommendations for Primary Cutaneous Melanoma.

Jessica Dowling1, Sean P McGregor2, Philip Williford3.   

Abstract

Primary cutaneous melanoma describes any primary melanoma lesion of the skin that does not have evidence of metastatic disease. This article reviews the current workup, treatment, and follow-up recommendations for primary cutaneous melanoma (stages 0, I, and II). Specific attention is focused on recent updates with regard to staging, sentinel lymph node biopsy, and surgical modalities.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Excision; Melanoma; Mohs; Primary; Sentinel; Staging

Mesh:

Year:  2019        PMID: 31466581     DOI: 10.1016/j.det.2019.06.001

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

1.  Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma.

Authors:  Ling Xue; Pingfan Wu; Xiaowen Zhao; Xiaojie Jin; Jingjing Wang; Yuxiang Shi; Xiaojing Yang; Yali She; Yaling Li; Changtian Li
Journal:  Int J Gen Med       Date:  2021-10-08

2.  A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.

Authors:  An-An Li; Fan Li; Min Lan; Yu Zhang; Dong Xie; Mei-Ying Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-10       Impact factor: 4.322

3.  Interleukin-7 regulates CD127 expression and promotes CD8+ T cell activity in patients with primary cutaneous melanoma.

Authors:  Hongxia He; Binjun Qiao; Shuping Guo; Hongzhou Cui; Ziyan Zhang; Junxia Qin
Journal:  BMC Immunol       Date:  2022-07-18       Impact factor: 3.594

4.  m5C-Related Signatures for Predicting Prognosis in Cutaneous Melanoma with Machine Learning.

Authors:  Maoxin Huang; Yi Zhang; Xiaohong Ou; Caiyun Wang; Xueqing Wang; Bibo Qin; Qiong Zhang; Jie Yu; Jianxiang Zhang; Jianbin Yu
Journal:  J Oncol       Date:  2021-08-04       Impact factor: 4.375

Review 5.  Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?

Authors:  Michael Kuske; Maximilian Haist; Thomas Jung; Stephan Grabbe; Matthias Bros
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.